$1.25
1.97% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US87583X1090
Symbol
TNGX

Tango Therapeutics Inc Stock price

$1.27
-0.63 33.16% 1M
-5.63 81.59% 6M
-1.82 58.90% YTD
-6.41 83.46% 1Y
-6.74 84.14% 3Y
-8.96 87.59% 5Y
-8.96 87.59% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.10 7.30%
ISIN
US87583X1090
Symbol
TNGX
Sector

Key metrics

Market capitalization $137.30m
Enterprise Value $-84.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.64
EV/Sales (TTM) EV/Sales -2.00
P/S ratio (TTM) P/S ratio 3.26
P/B ratio (TTM) P/B ratio 0.69
Revenue growth (TTM) Revenue growth 15.18%
Revenue (TTM) Revenue $42.07m
EBIT (operating result TTM) EBIT $-145.60m
Free Cash Flow (TTM) Free Cash Flow $-132.26m
Cash position $257.92m
EPS (TTM) EPS $-1.20
P/E forward negative
P/S forward 4.56
EV/Sales forward negative
Short interest 15.45%
Show more

Is Tango Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Tango Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tango Therapeutics Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Tango Therapeutics Inc forecast:

Buy
100%

Financial data from Tango Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
42 42
15% 15%
100%
- Direct Costs 2.50 2.50
40% 40%
6%
40 40
22% 22%
94%
- Selling and Administrative Expenses 39 39
43% 43%
92%
- Research and Development Expense 144 144
25% 25%
342%
-143 -143
30% 30%
-340%
- Depreciation and Amortization 2.50 2.50
40% 40%
6%
EBIT (Operating Income) EBIT -146 -146
28% 28%
-346%
Net Profit -130 -130
28% 28%
-310%

In millions USD.

Don't miss a Thing! We will send you all news about Tango Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tango Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 20...
Neutral
GlobeNewsWire
about one month ago
– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio ®  (abemaciclib) establis...
Neutral
GlobeNewsWire
2 months ago
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotech...
More Tango Therapeutics Inc News

Company Profile

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Barbara Weber
Employees 155
Founded 2017
Website www.tangotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today